Dataset Information

The effects of oligomycin administration and glutamine deprivation on metabolic profile of MCF7 breast cancer cell line measured using [1,2-13C2]-D-glucose and [U-13C5]-L-glutamine as tracers

ABSTRACT: This study aims to establish a comprehensive, genome-scale metabolic model (GSMM) combining different omics data of different regulatory levels of breast cancer cells in order to elucidate the way that these regulatory levels affect or determine each other. Together with transcriptomics, proteomics and metabolomics data obtained, fluxomics data was also to be integrated. In order to get the fluxomics data, MCF cells were incubated with either the medium containing [1,2-13C2]-D-glucose or [U-13C5]-L-glutamine for 8 or 24 hours. A good GSMM should answer any perturbations applied; therefore, different incubation conditions should be applied to generate different metabolic profiles that will help to test if the model of breast cancer works well. To this end, MCF cells were either administered oligomycine, which is an ATP synthase inhibitor, or were deprived of glutamine. Cells were counted before and after each incubation time so as to get the cell proliferation curve. Later, at the corresponding time points, cells and media were frozen to measure the concentrations of glucose, glutamine and lactate (not shown in the file) and the mass isotopomer distributions of glutamate, ribose, lactate, amino acids and TCA cycle intermediates (shown in the file). Finally, all these data was combined in order to estimate the flux rates of various reactions within the central carbon metabolism (not shown in the file). The fluxomics data obtained in this way is to be introduced in the GSMM designed.

OTHER RELATED OMICS DATASETS IN: PXD006449

INSTRUMENT(S): 5975C Series GC/MSD (Agilent)

SUBMITTER: Silvia Marin

PROVIDER: MTBLS183 | MetaboLights | 2021-01-18

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MTBLS183	Other
	FILES	Other
	a_MTBLS183_metabolic_characterization_metabolite_profiling_mass_spectrometry.txt	Txt
	i_Investigation.txt	Txt
	s_MTBLS183.txt	Txt

Items per page:

1 - 5 of 5

Publications

The landscape of tiered regulation of breast cancer cell metabolism.

Katzir Rotem R Polat Ibrahim H IH Harel Michal M Katz Shir S Foguet Carles C Selivanov Vitaly A VA Sabatier Philippe P Cascante Marta M Geiger Tamar T Ruppin Eytan E

Scientific reports 20191128 1

Altered metabolism is a hallmark of cancer, but little is still known about its regulation. In this study, we measure transcriptomic, proteomic, phospho-proteomic and fluxomics data in a breast cancer cell-line (MCF7) across three different growth conditions. Integrating these multiomics data within a genome scale human metabolic model in combination with machine learning, we systematically chart the different layers of metabolic regulation in breast cancer cells, predicting which enzymes and pa ...[more]

PMID: 31780802

Similar Datasets

Project description:Retinoids have been used as potential chemotherapeutic or chemo-preventive agents because of their differentiation, anti-proliferative, pro-apoptotic, and anti-oxidant effects. We investigated the effect of all trans- retinoic acid (ATRA) at different stages of the neoplastic transformation using an in vitro model of breast cancer progression. This model was previously developed by treating the human normal-like breast epithelial MCF-10F cells with high dose of estradiol and consist of five cell lines which shown a progressive neoplastic transformation: MCF-10F (normal stage), trMCF (premalignant stage), bsMCF (invasive stage) and caMCF (tumorigenic stage). In 3D-cultures, MCF-10F cells form tubules resembling the normal mammary gland although after treatment with high doses of estradiol, trMCF cells, formed tubules and, spherical masses which are an indication of cell transformation. By ring cloning, trMCF clone 11 which only formed spherical masses in collagen was isolated. Our results showed that the early transformed trMCF clone 11 cells shown a reduction of spherical masses and increased of tubules in collagen after being treated with 10-5M (10M-BM-5M) and 10-6M (1M-BM-5M) ATRA; the number of tubules was higher in cells treated with 10-6M ATRA (43% vs. 10% tubules). The invasive bsMCF and tumorigenic caMCF cells did not shown any changes in morphology after ATRA treatment. Analysis of expression studies in early transformed cells treated with 10-6M ATRA showed that 271 probes upregulated in trMCF clone 11 cells were downregulated after ATRA treatment and, 316 probes that were downregulated were upregulated after ATRA treatment in these cells to similar levels than the normal breast epithelial cells MCF-10F. These genes were involved in the aryl hydrocarbon receptor signaling, RAR Activation, xenobiotic metabolisms signaling, molecular mechanisms of cancer and cell morphology. Our results shown that ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process suggesting that ATRA could potentially be used to inhibit the progression of premalignant lesions of the breast such as ductal carcinoma in situ (DCIS). We investigated the effect of all trans- retinoic acid (ATRA) at different stages of the neoplastic transformation using an in vitro model of breast cancer progression. This model was previously developed by treating the human normal-like breast epithelial MCF-10F cells with high dose of estradiol and consist of five cell lines which shown a progressive neoplastic transformation: MCF-10F (normal stage), trMCF (premalignant stage), bsMCF (invasive stage) and caMCF (tumorigenic stage).